

## Special Issue

# Financial Toxicity of Cancer Treatment and Care

### Message from the Guest Editors

Financial toxicity (FT), which indicates the unexpected and unanticipated financial burden experienced by cancer patients receiving cancer treatment or follow-up care, is associated with an increased risk of negative outcomes and death. The risk of financial toxicity is influenced by the cancer type and severity, treatment received, age, income and type of health insurance. The impact of financial distress on cancer patients can include impaired health-related quality of life, not taking medications as prescribed to save money, and substandard quality of care. There are still some aspects of financial toxicity that have very limited data, or data that is out of date. We hope this Special Issue will allow researchers to more fully explore the current issues facing patients and their caregivers related to financial stresses.

In this Special Issue, original research articles, including both quantitative and qualitative designs, and reviews are welcome. Research areas may include (but are not limited to) the following:

Patient/family-level impact of financial toxicity;  
Potential interventions to mitigate financial toxicity.

---

### Guest Editors

Dr. Christopher J. Longo

DeGroote School of Business, Centre for Health Economics and Policy Analysis, McMaster University, Toronto, ON, Canada

Prof. Dr. Margaret Fitch

Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON M5S 1A1, Canada

---

### Deadline for manuscript submissions

closed (31 December 2023)



## Current Oncology

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 4.9  
Indexed in PubMed



[mdpi.com/si/111404](https://mdpi.com/si/111404)

*Current Oncology*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[currentoncology@mdpi.com](mailto:currentoncology@mdpi.com)

[mdpi.com/journal/  
currentoncol](https://mdpi.com/journal/currentoncol)





# Current Oncology

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 4.9  
Indexed in PubMed



[mdpi.com/journal/  
currenocol](https://mdpi.com/journal/currenocol)



## About the Journal

### Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

---

### Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology)